Literature DB >> 17263761

Metformin improves skin capillary reactivity in normoglycaemic subjects with the metabolic syndrome.

L G Kraemer de Aguiar1, C M Laflor, L Bahia, N R Villela, N Wiernsperger, D A Bottino, E Bouskela.   

Abstract

AIMS: Insulin resistance and a parental history of diabetes mellitus are independently associated with endothelial dysfunction. Oxidative stress has a pivotal role in the pathophysiology of vascular injury. Metformin, in addition to its glucose-lowering properties, has vasculoprotective effects. We investigated whether metformin has beneficial effects on the nutritive skin capillary circulation and deceases oxidative stress in a group at high risk for Type 2 diabetes mellitus (T2DM) and cardiovascular disease.
METHODS: Thirty normoglycaemic subjects with the metabolic syndrome (MS),who had first-degree relatives with T2DM, participated. The mean age was 39.1 +/- 8.4 years and body mass index (BMI) 35.7 +/- 4.8 kg/m2 (mean +/- SD).
SUBJECTS: were randomized 1 : 1 to receive placebo (n=14) or metformin (n=16; 1700 mg/day) in a double-blind study. At baseline and post treatment, blood and urine samples were collected for biochemical and 8-epi-prostaglandin F2alpha (8-epi-PGF2alpha) analysis, respectively. Microcirculation was assessed by nailfold videocapillaroscopy, analysing afferent (AF), efferent (EF) and apical (AP) diameters of capillary loops, functional capillary density (FCD), red blood cell velocity at rest (RBCV), after 1 min arterial occlusion (RBCVmax) and time (TRBCVmax)taken to reach it.
RESULTS: Groups did not differ significantly in anthropometric, clinical, laboratory or microvascular measurements at baseline. In the metformin group, weight,BMI, systolic blood pressure and fasting plasma glucose fell, and lipid profile and microcirculatory parameters FCD, AF, EF, AP, RBCVmaxand TRBCVmax improved (all P<0.01). No relationship between clinico-laboratory parameters and microvascular reactivity was observed, except for changes in total and low density lipoprotein-cholesterol and RBCVmax* 8-epi-PGF2alpha did not change significantly in either group.
CONCLUSIONS: Metformin improved skin capillary reactivity in normoglycaemic MS subjects independently of significant changes in 8-epi-PGF2alpha levels.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17263761     DOI: 10.1111/j.1464-5491.2007.02082.x

Source DB:  PubMed          Journal:  Diabet Med        ISSN: 0742-3071            Impact factor:   4.359


  10 in total

1.  Long-term dietary intake of selenium, calcium, and dairy products is associated with improved capillary recruitment in healthy young men.

Authors:  Caroline Buss; Carolina Marinho; Priscila Alves Maranhão; Eliete Bouskela; Luiz Guilherme Kraemer-Aguiar
Journal:  Eur J Nutr       Date:  2012-07-22       Impact factor: 5.614

2.  Postmaximal contraction blood volume responses are blunted in obese and type 2 diabetic subjects in a muscle-specific manner.

Authors:  Otto A Sanchez; Elizabeth A Copenhaver; Marti A Chance; Michael J Fowler; Theodore F Towse; Jane A Kent-Braun; Bruce M Damon
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-05-13       Impact factor: 4.733

3.  Metformin prevents endothelial oxidative stress and microvascular insulin resistance during obesity development in male rats.

Authors:  Jia Liu; Kevin W Aylor; Weidong Chai; Eugene J Barrett; Zhenqi Liu
Journal:  Am J Physiol Endocrinol Metab       Date:  2022-02-07       Impact factor: 4.310

Review 4.  Protection by metformin against severe Covid-19: An in-depth mechanistic analysis.

Authors:  Nicolas Wiernsperger; Abdallah Al-Salameh; Bertrand Cariou; Jean-Daniel Lalau
Journal:  Diabetes Metab       Date:  2022-05-31       Impact factor: 8.254

5.  Glycemic control prevents microvascular remodeling and increased tone in type 2 diabetes: link to endothelin-1.

Authors:  Kamakshi Sachidanandam; Jim R Hutchinson; Mostafa M Elgebaly; Erin M Mezzetti; Anne M Dorrance; Kouros Motamed; Adviye Ergul
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2009-01-28       Impact factor: 3.619

6.  Effects of metformin on blood lipid profiles in nondiabetic adults: a meta-analysis of randomized controlled trials.

Authors:  Shuwei Weng; Yonghong Luo; Ziyu Zhang; Xin Su; Daoquan Peng
Journal:  Endocrine       Date:  2020-01-16       Impact factor: 3.633

7.  Obesity, metabolic syndrome, impaired fasting glucose, and microvascular dysfunction: a principal component analysis approach.

Authors:  Diogo G Panazzolo; Fernando L Sicuro; Ruth Clapauch; Priscila A Maranhão; Eliete Bouskela; Luiz G Kraemer-Aguiar
Journal:  BMC Cardiovasc Disord       Date:  2012-11-13       Impact factor: 2.298

Review 8.  Metformin as a cellular protector; a synoptic view of modern evidences.

Authors:  Nicolas Wiernsperger
Journal:  J Nephropharmacol       Date:  2015-01-01

9.  Short-term treatment with metformin improves the cardiovascular risk profile in first-degree relatives of subjects with type 2 diabetes mellitus who have a metabolic syndrome and normal glucose tolerance without changes in C-reactive protein or fibrinogen.

Authors:  Luis Mauro Alvim de Lima; Nicolas Wiernsperger; Luiz Guilherme Kraemer-Aguiar; Eliete Bouskela
Journal:  Clinics (Sao Paulo)       Date:  2009-05       Impact factor: 2.365

10.  Effects of two weeks of metformin treatment on whole-body glycocalyx barrier properties in db/db mice.

Authors:  Bart J M Eskens; Coert J Zuurbier; Judith van Haare; Hans Vink; Jurgen W G E van Teeffelen
Journal:  Cardiovasc Diabetol       Date:  2013-12-05       Impact factor: 9.951

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.